Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential. Alterations of their secretion, in vivo degradation, and elimination in patients with chronic renal insufficiency (CRI) have not yet been characterized. Ten patients with CRI (aged 47 +/- 15 years, BMI 24.5 +/- 2.2 kg/m(2), and serum creatinine 2.18 +/- 0.86 mg/dl) and 10 matched healthy control subjects (aged 44 +/- 12 years, BMI 24.9 +/- 3.4 kg/m(2), and serum creatinine 0.89 +/- 0.10 mg/dl) were included. On separate occasions, an oral glucose tolerance test (75 g), an intravenous infusion of GLP-1 (0.5 pmol. kg(-1). min(-1) over 30 min), and an intravenous infusion of GIP (1.0 pmol. kg(-1). min(-1) over 30 min) were performed. Venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, C-peptide, GLP-1 (total and intact), and GIP (total and intact; specific immunoassays). Plasma levels of GIP (3-42) and GLP-1 (9-36 amide) were calculated. Statistics were performed using repeated-measures and one-way ANOVA. After the oral glucose load, plasma concentrations of intact GLP-1 and intact GIP reached similar levels in both groups (P = 0.31 and P = 0.87, respectively). The concentrations of GIP (3-42) and GLP-1 (9-36 amide) were significantly higher in the patients than in the control subjects (P = 0.0021 and P = 0.027, respectively). During and after the exogenous infusion, GLP-1 (9-36 amide) and GIP (3-42) reached higher plasma concentrations in the CRI patients than in the control subjects (P < 0.001 and P = 0.0033, respectively), whereas the plasma levels of intact GLP-1 and GIP were not different between the groups (P = 0.29 and P = 0.27, respectively). Plasma half-lives were 3.4 +/- 0.6 and 2.3 +/- 0.4 min for intact GLP-1 (P = 0.13) and 5.3 +/- 0.8 and 3.3 +/- 0.4 min for the GLP-1 metabolite (P = 0.029) for CRI patients vs. healthy control subjects, respectively. Plasma half-lives of intact GIP were 6.9 +/- 1.4 and 5.0 +/- 1.2 min (P = 0.31) and 38.1 +/- 6.0 and 22.4 +/- 3.0 min for the GIP metabolite (P = 0.032) for CRI patients vs. healthy control subjects, respectively. Insulin concentrations tended to be lower in the patients during all experiments, whereas C-peptide levels tended to be elevated. These data underline the importance of the kidneys for the final elimination of GIP and GLP-1. The initial dipeptidyl peptidase IV-mediated degradation of both hormones is almost unaffected by impairments in renal function. Delayed elimination of GLP-1 and GIP in renal insufficiency may influence the pharmacokinetics and pharmacodynamics of dipeptidyl peptidase IV-resistant incretin derivatives to be used for the treatment of patients with type 2 diabetes.

[1]  John R. Christiansen,et al.  GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans , 1989, Digestive Diseases and Sciences.

[2]  Z. Lojda.  Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase) , 1979, Histochemistry.

[3]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. , 2001, Diabetes.

[4]  Xia Li,et al.  Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  S. Bloom,et al.  The pharmacokinetics of porcine glucose‐dependent insulinotropic polypeptide (GIP) in man , 1982, European journal of clinical investigation.

[7]  J. Levy,et al.  Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. , 2002, Diabetes care.

[8]  J. López-Novoa,et al.  Renal catabolism of human glucagon-like peptides 1 and 2. , 1990, Canadian journal of physiology and pharmacology.

[9]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[10]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  J. Holst,et al.  Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.

[12]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[13]  K. Sirinek,et al.  Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. , 1984, American journal of surgery.

[14]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[15]  I. Valverde,et al.  Renal catabolism of truncated glucagon-like peptide 1. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[16]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[17]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[18]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[19]  J. Sturis,et al.  Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. , 2002, Diabetes.

[20]  D. Drucker.  Biological actions and therapeutic potential of the glucagon-like peptides. , 2002, Gastroenterology.

[21]  D. Drucker,et al.  Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. , 2003, Diabetes.

[22]  M. Nauck,et al.  Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. , 2003, BioDrugs.

[23]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[24]  J. Sturis,et al.  Bedtime Administration of NN 2211 , a Long-Acting GLP-1 Derivative , Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes , 2002 .

[25]  L. B. Knudsen,et al.  Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. , 1996, European journal of pharmacology.

[26]  J. Holst,et al.  Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. , 1999, Endocrinology.

[27]  G. Shull,et al.  An alternate pathway of cAMP-stimulated Cl secretion across the NKCC1-null murine duodenum. , 2002, Gastroenterology.

[28]  J. Holst,et al.  In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  C. Montrose‐Rafizadeh,et al.  High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor* , 1997, The Journal of Biological Chemistry.

[30]  P. Flatt,et al.  Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. , 2002, The Journal of endocrinology.

[31]  J. Holst,et al.  The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide , 1998, Peptides.

[32]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[33]  J. Holst,et al.  Differential regional metabolism of glucagon in anesthetized pigs. , 2003, American journal of physiology. Endocrinology and metabolism.

[34]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[35]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[36]  C. Lowy,et al.  Serum-growth hormone and glucose intolerance in renal failure. , 1968, Lancet.

[37]  C. Price,et al.  Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). , 1997, Clinical chemistry.

[38]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[39]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[40]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[41]  J. Holst,et al.  Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. , 1996, Scandinavian journal of gastroenterology.

[42]  J. Holst.  Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential , 1999, Trends in Endocrinology & Metabolism.

[43]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[44]  M. Nauck,et al.  Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. , 1989, The Journal of clinical endocrinology and metabolism.

[45]  D. D’Alessio,et al.  Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. , 2003, The Journal of clinical endocrinology and metabolism.

[46]  J. Holst,et al.  All products of proglucagon are elevated in plasma from uremic patients. , 1992, The Journal of clinical endocrinology and metabolism.

[47]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[48]  P. Layer,et al.  Is GLP-1 amide an endogenous antagonist at GLP-1 receptors? , 1994 .

[49]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[50]  C. Price,et al.  Cystatin C: an improved estimator of glomerular filtration rate? , 2002, Clinical chemistry.

[51]  W. Creutzfeldt,et al.  The incretin concept today , 1979, Diabetologia.

[52]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.